• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Legal & Compliance Thompson Rahsaan sold $221,004 worth of shares (24,000 units at $9.21), decreasing direct ownership by 36% to 42,666 units (SEC Form 4)

    6/30/25 5:02:34 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZVRA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Thompson Rahsaan

    (Last) (First) (Middle)
    C/O ZEVRA THERAPEUTICS, INC.
    1180 CELEBRATION BOULEVARD, SUITE 103

    (Street)
    CELEBRATION FL 34747

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ZEVRA THERAPEUTICS, INC. [ ZVRA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) X Other (specify below)
    Chief Legal & Compliance Secretary
    3. Date of Earliest Transaction (Month/Day/Year)
    06/26/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/26/2025 S(1) 24,000 D $9.2085(2) 42,666 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Adoption date of referenced 10b5-1(c) plan is: 03-27-2025
    2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.11 to $9.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
    /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Rahsaan W. Thompson 06/30/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ZVRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZVRA

    DatePrice TargetRatingAnalyst
    1/8/2025$25.00Overweight
    Cantor Fitzgerald
    10/7/2024$20.00Buy
    Guggenheim
    9/24/2024$17.00Mkt Outperform
    JMP Securities
    9/24/2024$18.00 → $25.00Buy
    Maxim Group
    4/2/2024$12.00 → $18.00Buy
    Maxim Group
    3/12/2024Outperform
    William Blair
    3/17/2023$12.00Buy
    Maxim Group
    More analyst ratings

    $ZVRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Zevra Therapeutics with a new price target

      Cantor Fitzgerald resumed coverage of Zevra Therapeutics with a rating of Overweight and set a new price target of $25.00

      1/8/25 8:49:26 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Zevra Therapeutics with a new price target

      Guggenheim initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $20.00

      10/7/24 8:28:23 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Zevra Therapeutics with a new price target

      JMP Securities initiated coverage of Zevra Therapeutics with a rating of Mkt Outperform and set a new price target of $17.00

      9/24/24 8:29:54 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Watton Corey Michael bought $2,352 worth of shares (300 units at $7.84), increasing direct ownership by 20% to 1,800 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      3/31/25 8:05:01 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bode John B bought $79,624 worth of shares (10,000 units at $7.96), increasing direct ownership by 33% to 40,000 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      3/21/25 4:06:49 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Watton Corey Michael bought $3,958 worth of shares (500 units at $7.92), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      10/16/24 4:46:26 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    SEC Filings

    See more
    • SEC Form 8-K filed by Zevra Therapeutics Inc.

      8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      5/29/25 4:42:38 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Zevra Therapeutics Inc.

      DEFA14A - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      5/21/25 4:05:58 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Zevra Therapeutics Inc.

      10-Q - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      5/13/25 5:15:59 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care